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Abstract 7 
Deviation in pulmonary surfactant structure-function activity can impair airway patency and lead to respiratory 8 
disorders.  This novel study aims to evaluate the influence cigarette / e-cigarette vapour has on model 9 
surfactant films located within a simulated pulmonary environment using a lung biosimulator.  10 
Chromatographic analysis confirmed that nicotine levels were consistent with the sampling regimen 11 
employed.  On exposure to smoke vapour, Langmuir isotherms exhibited condensed character and a 12 
significant reduction in maximum surface pressure was noted in all cases.  Langmuir isocycles, reflective of the 13 
human breathing cycle, demonstrated condensed character on smoke vapour delivery.  A reduction in the 14 
maximum surface pressure was clear only in the case of cigarette vapour application.  The components of 15 
cigarette vapour can cause oxidative damage to pulmonary surfactant and impair recycling.  Neutral nicotine 16 
molecules can weaken the structure of the monolayer and cause destabilisation.  A protective effect was 17 
evident in the case of repeated surfactant compression – relaxation cycles (i.e. the ability to reduce the surface 18 
tension term was impaired less), demonstrating a likely innate biological defensive mechanism of the lung.  E-19 
cigarette vapour appeared to have a reduced impact on surfactant performance, which may hold value in 20 
harm reduction over the longer term. 21 
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1. Introduction 39 
  40 
The primary function of the lung is to permit gaseous exchange between the body and the 41 
atmosphere.  The main site for such exchange is the alveolar space, which exhibits a moist and highly 42 
vascularised surface of approximately 70m2 [1].  The naturally occurring fluid that bathes the 43 
alveolar lining is subject to considerable surface tension that can force structural collapse on 44 
exhalation [2].  In order to counter this effect, and also minimise the work of breathing, a complex 45 
and highly surface active mix called pulmonary surfactant is distributed at the alveolar air-liquid 46 
interface [3].  The arrangement results in pulmonary surfactant presenting as the initial contacting 47 
surface for aerosolised material.   Prime examples of such material include respirable therapeutic 48 
formulations [4] and, importantly for work presented herein, environmental toxins such as cigarette 49 
/ e-cigarette vapour [5 & 6].  50 
 51 
Pulmonary surfactant is synthesised and secreted by alveolar type II cells located in the deep lung.  52 
This endogenous substance exists as an insoluble film that coats the alveolar air-liquid interface [7].  53 
As a result of inherent material characteristics, pulmonary surfactant is capable of reducing the 54 
surface tension term to near zero values [8 & 9], which in turn facilitates alveolar stability [3].  In 55 
order to achieve this, a dynamic interplay exists between the phospholipid molecules and surfactant 56 
specific proteins within the naturally occurring blend.  With regard to the former, 57 
dipalmitoylphosphatidylcholine (DPPC) predominates and is principally responsible for the surface 58 
tension lowering properties of the material [8].  As this amphiphilic molecule undergoes a gel to 59 
liquid transition at 41°C, thus the ability to respread across the alveolar air-liquid interface is limited 60 
during the breathing cycle [1].  Consequently, additional species are required in order to maintain 61 
fluidity and support surfactant respreading.  For instance, palmitoyloleoylphosphatidylglycerol 62 
(POPG) facilitates effective respreading of pulmonary surfactant following compression [2].  63 
Commercially available lung surfactant replacement preparations (e.g. Survanta®) are frequently 64 
prescribed for the management of neonatal respiratory distress syndrome [10].  Such products are 65 
often supplemented with palmitic acid (PA), which permits comparable in vivo respreading profiles 66 
[11].  Thus, throughout this work an appropriate blend of DPPC, POPG and PA is applied to reflect 67 
the key lipid fractions of pulmonary surfactant located at the alveolar air-liquid interface. 68 
 69 
 70 
 71 
3 | P a g e  
 
A Langmuir trough may be used within the laboratory setting to represent the alveolar air-liquid 72 
interface [4, 7 & 12].  Here, amphiphilic molecules arrange themselves as per the in vivo scenario 73 
with their fatty acyl chains displaced away from the supporting aqueous subphase and the polar 74 
head groups in direct contact [1].  Scope exists to control environmental parameters with the option 75 
to operate at a temperature of 37°C and conduct investigations at elevated relative humidity, as per 76 
the (deep) lung; this arrangement may now be investigated via the lung biosimulator [13].  77 
Lateral forces may be applied to simulated pulmonary surfactant monolayers in isolation or indeed 78 
succession to achieve expansion / compression cycles reflective of the human breathing pattern 79 
[14].  Typical outputs from the approach include Langmuir pressure-area (-A) isotherms and 80 
isocycles, which can be applied to monitor the response of the amphiphilic material when exposed 81 
to environmental stressors (i.e. cigarette smoke).  For example, in 2003 Bringezu and co-workers 82 
applied Langmuir monolayer technology to evaluate the effect of environmental tobacco smoke 83 
(ETS) on simulated pulmonary surfactant structure-function activity [11]. The investigation utilised a 84 
mixture of DPPC, POPG and PA in the ratio of 69:20:11 to maintain the lipid fraction consistent with 85 
clinically used replacement pulmonary surfactant [12]. Here, the surfactant blend was applied to a 86 
supporting aqueous subphase that had been previously exposed to ETS.  The results from the study 87 
suggested that ETS exposure impacts upon monolayer phase behaviour and morphology leading to a 88 
higher minimum surface tension (i.e. reduced maximum surface pressure) and impaired lung 89 
function.  90 
Tobacco smoking has now become one of the most pervasive habits in modern day society [1].  91 
Tobacco smoke consists of a range of chemical compounds, including aldehydes, amides, amines, 92 
carboxylic acids, ketones, esters, phenols and hydrocarbons.  The chemical compounds can be 93 
further divided into three classes, tobacco-specific nitrosamines (TSNAs), polyaromatic hydrocarbons 94 
(PAHs) and volatile organic compounds (VOCs). Compounds assigned to TSNAs, such as N'-95 
nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) comprise of 96 
chemicals of known carcinogenic affect, which occur during the manufacturing, fermentation and 97 
combustion of tobacco. PAHs, such as naphthalene are located in the particulate composition of 98 
tobacco smoke and are produced during the incomplete combustion of the organic material.   99 
 100 
 101 
 102 
 103 
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In order to minimise exposure to the toxic constituents of tobacco smoke, and hence reduce 104 
associated long-term deleterious effects, the consumer now has available a range of potential 105 
reduced exposure products (PREPs) to purchase [15].  One of the most recently released PREPs is the 106 
e-cigarette, which is becoming increasingly popular [16].  As e-cigarettes imitate traditional 107 
cigarettes, they not only deliver nicotine but also simulate the process of smoking to satisfy 108 
psychological cravings.  However, in contrast to traditional cigarettes, e-cigarettes do not involve 109 
tobacco combustion.  Here, the consumer inhales a vapour that is produced by heating a solution 110 
consisting of processed nicotine extract from tobacco leaves, water, glycerine and / or propylene 111 
glycol along with flavourings [17].  Potentially harmful constituents present in e-cigarette vapour 112 
include carbonyl compounds, volatile organic compounds, TSNAs and heavy metals [17].  All can 113 
have toxic, irritating and / or carcinogenic effect on the human body [18].    114 
This novel study aims to monitor the response of simulated pulmonary surfactant monolayers when 115 
challenged with cigarette / e-cigarette vapour under physiologically relevant conditions (i.e. 37°C 116 
and elevated relative humidity).  For the first time we apply a patented technology platform to 117 
quantitatively probe the influence of cigarette / e-cigarette vapour on the performance of a mixed 118 
surfactant film located within an environment reflective of the (deep) lung.  This work is of interest 119 
because it provides a strategy by which to better understand fundamental interactions taking place 120 
at a biological interface that is crucial to sustaining life.  The timely work will further current 121 
understanding of the health impacts associated with smoking cigarettes / e-cigarettes.  Throughout 122 
the piece consideration will be given to the reproducibility of nicotine presentation within the 123 
sampling routine, the identification of chemical species within aerosolised samples and potential 124 
mechanisms of interaction with simulated pulmonary surfactant.   125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
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2. Materials and Methods 135 
 136 
2.1 Materials 137 
 138 
The surfactants DPPC (Avanti Polar Lipids, USA. Lot: 160PC-312), POPG (Avanti Polar Lipids, USA. Lot: 139 
160-181PG-131) and PA (Sigma-Aldrich, UK. Lot: PO500) were of analytical grade and used as 140 
supplied.  Chloroform (CHCl3) (Sigma-Aldrich, UK) of analytical grade (≥ 99.9%) was employed to 141 
clean contacting surfaces and as the spreading solvent.  Methanol (HPLC Grade, Sigma-Aldrich, 142 
34860, Lot: STBF7002V) was employed as the solvent during smoke analysis via gas chromatography. 143 
Ultrapure water (Purite, UK), demonstrating a resistivity of 18.MΩcm, was used both during cleaning 144 
procedures and as the Langmuir monolayer aqueous subphase.  Marlboro Gold cigarettes along with 145 
Blu Classic (first generation) and Eleaf iStick 50W, with Eleaf GS Air Tank atomiser (3rd generation) e-146 
cigarettes were purchased through a retail sources.  The strength of the e-cigarette refills was 147 
represented by the amount of nicotine (i.e. mg) per 1ml of the liquid solution. The cartridges used 148 
with the first generation device contained 18mg of nicotine per unit.  The batteries of each device 149 
were fully charged before each test to facilitate reproducible data collection.   150 
 151 
2.2 Methods 152 
 153 
2.2.1 Langmuir Monolayer Preparation 154 
 155 
Surfactant monolayers were produced using a Langmuir trough (Model 102M, Nima Technology, 156 
UK).  Surfactant free tissues (Kimtech Science, Kimberley-Clark Professional, 75512, UK) were soaked 157 
in chloroform and used to clean all contacting glassware and surfaces.  Background tests to monitor 158 
surface pressure in the absence of surfactant material were performed to ensure trough cleanliness, 159 
which was accepted at surface pressures of 0.4mN/m or less on complete barrier compression.  A 160 
spreading solution composed of DPPC, POPG and PA in the ratio 69:20:11 was produced to reflect 161 
appropriate lipid fractions at the alveolar air-lipid interface by dissolving the surfactant material in 162 
chloroform to a concentration of 1 mg/ml.  In total, 10µl of this solution was delivered to the surface 163 
of the ultrapure water subphase (50ml) at pH 7 by dropwise addition using a Hamilton microsyringe.  164 
The volume of 10µl was chosen so as to achieve a steady transition from the gaseous phase through 165 
to condensed phases on barrier compression and prevent saturation of the π-A isotherms / isocycles 166 
at the solid phase point.   167 
 168 
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A period of 10 minutes was allowed to allow chloroform evaporation and surfactant spreading over 169 
the 70cm2 area.  The polytetrafluoroethylene trough barriers were programmed to move to the 170 
centre of the trough at a rate of 25cm2/min.  Plots of surface pressure vs. percentage trough area for 171 
the surfactant system at 37°C and elevated humidity (e.g. 80% RH) were collected using a Wilhelmy 172 
plate, formed from Whatman 44 filter paper, at the centre of the compartment. 173 
 174 
2.2.2 Cigarette / e-cigarette Vapour Generation 175 
 176 
The vapour collection regimen involved taking 2 puffs from the cigarettes / e-cigarettes of 50ml total 177 
volume, over a 4-second puff duration with a 30-second puff interval [19].  The vapour was collected 178 
in a 250ml quick fit round bottom flask with 3 outlets.  Each cigarette / e-cigarette was connected to 179 
a Teflon mouthpiece that was linked to one of the outlets of the round bottom flask using 180 
appropriate tubing.  The second outlet, of the same size was connected to a 500ml separating funnel 181 
and the third outlet was closed with stopper to produce an airtight system.  The experimental 182 
arrangement for smoke collection is presented in Figure 1. 183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
Figure 1.  The arrangement applied to collect smoke vapour aliquots.          195 
                                                  196 
Teflon mouthpiece 
Transfer tubing 
Round bottom 
flask 
Fume hood 
Separating funnel 
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Before each cigarette / e-cigarette was activated, a total of 100ml of water was poured into the 197 
separating funnel (i.e. equivalent to 2 puffs).  On activation, smoke vapour was collected in the 198 
round bottom flask by withdrawing the 50ml of water from the funnel, with the next puff drawn 199 
after 30 seconds [19].  Once the second vapour aliquot was obtained, the round bottom flask 200 
containing smoke was disconnected from the separating funnel and mouthpiece and the two outlets 201 
are closed with stoppers to hold the smoke inside the flask.   202 
 203 
2.2.3 Nicotine Quantification / Smoke Component Determination 204 
 205 
Following the collection of each vapour sample, a total of 2ml of methanol was added to the round 206 
bottom flask to solubilise the aerosolised material.  Each sample was then filtered with a 0.45m 207 
syringe filter into a glass vial insert.  Analysis of nicotine standards and smoke extracts was carried 208 
out on an Agilent 7980GC with flame ionisation detection (FID).  The analytical column selected was 209 
an Agilent J&W DB-1 (30m x 0.250mm x 0.50m), with a column temperature of 160°C (isocratic).  210 
The injection type was 1l split (10:1) (20ml/min 250°C), with nitrogen selected as the carrier gas 211 
and the flame ionisation detector temperature programmed at 250°C.  Nicotine standards ranging 212 
from 0.0078 - 1mg/ml were constructed for nicotine quantification of the vapour extracts.  213 
Standards displayed excellent linearity with R2 values >0.999.  The analysis of 5 replicate smoke 214 
samples per cigarette/e cigarette was undertaken. 215 
Evaluation of vapour components was determined using an Agilent 6980GC with 5975MS detection. 216 
The column was an Agilent J&W HP5-MSUI (30m x 0.250mm x 0.25m) with split (10:1) injection of 217 
1l. The oven temperature were: 50°C for 5mins, 20°C/min to 255°C held for 1 min, 20°C/min to 218 
300°C held for 5 mins. The mass spectrometer was run in full scan mode from 40-500 AMU.  Mass 219 
spectra for recorded peaks were further evaluated using the NIST database (MS search programme 220 
Version 2.0, NIST, MSS Ltd., Manchester, England). 221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
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2.2.4 Vapour Addition to Simulated Pulmonary Surfactant Monolayers 232 
 233 
In order to assess the impact of smoke vapour on simulated pulmonary surfactant monolayers under 234 
physiologically relevant conditions, the aerosolised material was transferred from the round 235 
bottomed flask to the enclosed lung biosimulator [13], as detailed in Figure 2, using compressed air.  236 
Initially, baseline data was collected in the absence of cigarette / e-cigarette vapour.  Subsequently, 237 
the smoke vapour acquired from either the cigarettes or e-cigarettes was delivered to the test zone.  238 
In each case, a period of 10 minutes was allowed for interaction between each species under 239 
consideration.   240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
Figure 2.  A schematic detailing the lung biosimulator. 254 
 255 
 256 
 257 
 258 
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To obtain Langmuir isotherms, a single compression was applied towards the centre of the trough at 259 
a rate of 25cm2/min.  This relatively slow speed was chosen to closely observe the direct impact of 260 
cigarette / e-cigarette vapour on both the physical state of the simulated pulmonary surfactant plus 261 
compression performance.  With respect to Langmuir isocycle tests, a total of 14 compression-262 
expansion cycles were undertaken at a speed of 100cm2/min.  This faster compression speed is more 263 
representative of the human breathing cycle and provides an insight into system dynamics on 264 
exposure to cigarette / e-cigarette vapour.  In this case, the first 4 cycles were used to condition the 265 
monolayer such that the equilibrium position was attained.  This approach enabled a clearer 266 
depiction of the influence of the cigarette / e-cigarette vapour on the simulated pulmonary 267 
surfactant monolayer.  All Langmuir isotherm tests were repeated five times, whilst Langmuir 268 
isocycles were repeated three times and averaged data was used to generate the plots presented 269 
herein.  On test completion, the remaining vapour was removed from the lung biosimulator by 270 
directing through a tube to a nearby fume hood using compressed air.  271 
 272 
2.2.5 The Compressibility of Langmuir Monolayers 273 
 274 
The compressibility term relating to a Langmuir monolayer refers to the ability of the material to 275 
lower the surface tension at the air-liquid interface with minimal change in surface area [20].  276 
Surfactant films should ideally have a low compressibility value such that gaseous exchange can take 277 
place over a large surface area [21].  The lower the compressibility term, the more rigid the 278 
surfactant film is (i.e. the material is of low elasticity), with the opposite being true [22 & 23].  The 279 
parameter is calculated as detailed in Equation 1. 280 
 281 
Compressibility =
1
A
x
1
m
 282 
 283 
Equation 1. Simulated pulmonary surfactant compressibility determination. 284 
 285 
Where A represents the relative surface area and m the slope of the isotherm.  Here, ‘m’ was 286 
calculated via ‘m =  
𝑦2−𝑦1
𝑥2−𝑥1
’ over the surface pressure range of 10-30mN/m, whereby ‘y’ and ‘x’ values 287 
characterise surface pressure and area values, respectively [20].  288 
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3.  Results & Discussion 289 
 290 
3.1 Chemical Analysis of Smoke Vapour and Potential Impact on the Body 291 
 292 
Cigarette smoke contains thousands of chemical components, some of which are naturally occurring 293 
within the tobacco plant whilst others are added as additives during manufacture [24].  The nicotine 294 
component of the Marlboro Gold cigarette vapour tested herein was 0.043mg/ml ± 0.009, the 295 
quantity of this compound corresponded to that stated by the manufacturing company.  The 1st 296 
generation e-cigarette vapour produced a mean nicotine concentration of 0.048 mg/ml ± 0.006, with 297 
the 3rd generation e-cigarette vapour producing a value of 0.035 mg/ml ± 0.003.   The data 298 
demonstrated good reproducibility through all cigarette types. 299 
 300 
3.2 Gas Chromatography / Mass Spectroscopy Data 301 
 302 
GC-MS analysis of the cigarette / e-cigarette vapour component composition is illustrated in Figure 3a 303 
and Figure 3b.   304 
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 305 
Figure 3.  The principal components of cigarette vapour as determined by GC-MS. (a) cigarette vapour; (b) e-306 
cigarette vapour. 307 
 308 
The analysis confirms that nicotine and the related minor alkaloid components are the most abundant 309 
compounds within the cigarette vapour.  In addition, the vapour sample demonstrated a proportion 310 
of additive compounds.  The compounds representing the ‘other’ section included amines, and smoke 311 
related vapours, such as toluene.  With reference to the composition data relating to both the 1st and 312 
3rd generation e- cigarette vapour, it is apparent that nicotine is present, but it is not the major 313 
component.  The addition of propylene glycol and glycerin to the e-cigarette formulations accounts 314 
for a large proportion of the compounds present (i.e. >75% of the total composition) [18]. 315 
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Toluene and xylene were detected within the cigarette vapour extract by the GC-MS element of this 316 
investigation.  Exposure to the former can be detrimental to white blood cell function and this can in 317 
turn pre-dispose to respiratory tract infections [25].  Furthermore, exposure to xylene at levels 318 
greater than 200 ppm can irritate the lungs leading to acute shortness of breath accompanied by 319 
chest pain [26].   320 
In terms of the e-cigarette vapour, this route of nicotine administration to the body may be 321 
considered less harmful than the more natural, counterpart products.  With regard to this system of 322 
nicotine delivery, during 2011 Trehy and co-workers documented that the composition of refill 323 
products varies considerably as a result it is difficult to fully evaluate the hazards related to 324 
electronic cigarette usage [27].  The content of the aerosol generated from e-cigarette is highly 325 
variable, not only among different products but also within different samples of the same e-liquids 326 
[16, 17, 27, 28, 29 & 30].  Therefore, we suggest that further work is required to better understand 327 
the impact of the spectrum of e-cigarette products may have on pulmonary function. 328 
During this work we have carefully replicated the main stages of cigarette / e-cigarette use via 329 
reference to a typical puffing regimen [19] and applied the acquired vapour to a test zone housing a 330 
model pulmonary surfactant system representative of typical in vivo lipid fractions under 331 
physiologically relevant conditions [11].  The accepted mechanism of action for pulmonary 332 
surfactant, and model mixtures thereof, revolves around the unsaturated lipid fraction (e.g. POPG) 333 
forming a fluid-like liquid-expanded matrix to separate phases rich in condensed saturated lipids 334 
(e.g. DPPC) [1 & 31].  The delicate coexistence between each phase at the alveolar air-liquid 335 
interface is essential for effective surfactant function (i.e. to regulate surface viscosity and lower 336 
surface tension) [11, 14 & 31].  Clearly, any disruption to the synergy between the liquid-expanded 337 
and liquid-condensed phases forming the surfactant film can have a detrimental impact on gross 338 
lung function [1 & 21].  Within the laboratory setting, deviation in recorded Langmuir pressure-area 339 
isotherms and / or isocycles provides direct evidence of changes to overall surfactant performance.340 
  341 
 342 
 343 
 344 
 345 
 346 
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3.3 Langmuir Pressure – Area Isotherms 347 
 348 
Langmuir pressure-area isotherms were acquired for the simulated pulmonary surfactant systems 349 
when exposed to either cigarette or e-cigarette vapour under conditions reflective of the (deep) 350 
lung; relevant data are presented in Figures 4 and 5, respectively.  All systems exhibit two-351 
dimensional phase changes over the course of compression; movement through the gaseous, 352 
expanded and condensed phases is confirmed on gradient change from right to left.  Here, the 353 
compressibility parameter was considered with the slope of the trace used as a marker for the 354 
compressibility of the two-dimensional film; where the steeper the slope, the harder it is to 355 
compress the surfactant monolayer [32].   356 
 357 
 358 
Figure 4.   A Langmuir pressure-area isotherm detailing the response of a simulated pulmonary surfactant 359 
monolayer to cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated 360 
relative humidity.  Averaged data of 5 replicates presented with standard error of the mean displayed. 361 
 362 
On inspection of the data presented in Figure 4, it is clear that the administration of cigarette vapour 363 
to the test zone did influence simulated pulmonary surfactant structure-function activity.  Here, the 364 
ability to attain low surface tension values at any given relative area is reduced and there is an 365 
increase in the ease of compression under physiologically relevant conditions (i.e. the monolayer is 366 
more compressible).   367 
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In the case of the model surfactant system studied herein, the highest surface pressure recorded in 368 
the absence of cigarette smoke was 41mN/m.  This value was as a direct result of applying 10µl of 369 
the surfactant spreading solution (1mg/ml) to the supporting aqueous subphase, which was deemed 370 
appropriate to achieve smooth lipid phase transitions during compression and prevent solid phase 371 
saturation at minimal trough areas.  If a larger spreading solution volume were to be applied to the 372 
aqueous subphase then the maximum surface pressure would rise (e.g. attain a value of 373 
approximately 70mN/m).  On application of cigarette vapour, the value of 41mN/m diminished to 374 
32mN/m.  Hence, the capacity to lower the surface tension at full monolayer compression was 375 
reduced by 22%.  In addition, exposure of cigarette vapour resulted in the monolayer exhibiting a 376 
condensed character (i.e. being transposed to the left of the baseline plot).  Comparable trends, as 377 
those noted here, would be anticipated at higher surface pressure values (e.g. 70mN/m) [11]. 378 
A similar response was noted when 1st and 3rd generation e-cigarette vapour was delivered to the 379 
test zone.  Once again the baseline plot for our system exhibited a maximum surface pressure of 380 
41mN/m (i.e. due to the application of 10µl of material) with reduction in the term evident on 381 
exposure to 1st generation and 3rd generation e-cigarette vapour; namely 32mN/m and 36mN/m, 382 
respectively.  It is interesting to note that on delivery of the 1st generation e-cigarette vapour an 383 
identical reduction in the surface pressure term of 22% was noted.   This deviation was less in the 384 
case of the 3rd generation product, namely a 12% reduction.  The presence of e-cigarette vapour led 385 
to a reduction in the maximum surface pressure from the baseline data, this finding is statistically 386 
significant due to the absence of overlap in the presented standard error of the mean bars.  387 
Furthermore, as previously noted exposure to e-cigarette vapour caused a clear decrease in surface 388 
pressure at any corresponding area.  389 
 390 
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 391 
Figure 5.   Langmuir pressure-area isotherm data outlining the response of a simulated pulmonary surfactant 392 
monolayer to e-cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated 393 
relative humidity.  Averaged data of 5 replicates presented with standard error of the mean displayed. 394 
 395 
Similar responses to those outlined above have been noted within the literature [11].  All data 396 
presented within this piece are reflected of the in vivo situation where smoke vapour would interact 397 
with pulmonary surfactant via a ‘top-down’ approach.  In this instance, the hydrocarbon chains of 398 
the phospholipid molecules were primarily exposed to those chemicals within the smoke aliquots.  399 
Therefore, this work considers real-world interfacial interactions that can potentially compromise 400 
the biological function of the lung.  Furthermore, in support of our findings Kannisto and Yhteiskoulu 401 
reported functional changes in the lipid fraction of pulmonary surfactant as a result of phospholipid 402 
degradation and / or the penetration of nicotine molecules into the two-dimensional film during 403 
their 2006 study [33].  404 
 405 
3.3.1 Langmuir Isotherm Compressibility Analysis 406 
 407 
In order to quantify the impact of cigarette / e-cigarette vapour had on simulated pulmonary 408 
surfactant compressibility Equation 1 was applied.  Here, the slope of the Langmuir pressure-area 409 
isotherm was considered along the liquid-expanded to liquid-condensed transition.  That is to say 410 
between the surface pressures of 10mN/m to 30mN/m at the specific relative trough areas of 40%, 411 
50% and 70%.  Compressibility data for each system is presented in Figure 6. 412 
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 413 
 414 
Figure 6. The compressibility of simulated pulmonary surfactant monolayers at pre-defined relative trough 415 
areas in the absence and presence of cigarette / e-cigarette vapour.  In all cases of single monolayer 416 
compression (i.e. Langmuir isotherms), the delivery of such vapour to the test zone increased the 417 
compressibility term. 418 
 419 
On exposure to cigarette / e-cigarette vapour, the compressibility term increased in all cases.  420 
Greater compressibility values indicate that the surfactant film becomes less rigid in nature and 421 
more elastic (i.e. easier to compress when compared to the baseline).  This effect is more 422 
pronounced in the case of exposure to cigarette vapour.  The impact on monolayer compressibility is 423 
limited in the case of the 3rd generation e-cigarette.   424 
Although the use of Langmuir isotherms is not representative of the human breathing cycle, which is 425 
dynamic in nature, we believe that the information obtained from this largely static system can 426 
provide insight into the way in which environmental toxins (e.g. cigarette / e-cigarette vapour) can 427 
influence individual molecular species that are in the main fully exposed at the alveolar air-liquid 428 
interface (i.e. when in the gaseous phase).  Here, we liken this situation to a lone soldier under 429 
attack from an opposing force. 430 
 431 
 432 
 433 
 434 
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In all cases, exposure to cigarette / e-cigarette vapour resulted in the simulated pulmonary 435 
surfactant monolayer exhibiting a condensed character.  Consequently, the ability to reduce the 436 
surface tension term was impaired across all relative trough areas during compression to the centre 437 
of the compartment.  In addition, there was an apparent increase in monolayer compressibility.  438 
Clearly, exposure to vapour from all platforms had a detrimental impact on simulated pulmonary 439 
surfactant performance with exposure to cigarette vapour and the 1st generation e-cigarette vapour 440 
being the most significant.   There are a number of reasons to explain the notable trend in the data 441 
sets presented herein.  A previously reported aspect involves a reduction in phospholipid content 442 
within the surfactant film due to exposure to the chemical constituents of smoke vapour (e.g. free 443 
radicals and oxidising agents) [11].  Importantly, we believe that a key mechanism of surfactant film 444 
degradation lies in the ability of neutral nicotine molecules within smoke vapour to penetrate in-445 
between the relatively exposed phospholipid polar head groups of the surfactant film.  On 446 
inhalation, nicotine in the unionised form is able to enter the body and can readily pass across 447 
membrane structures as opposed to protonated nicotine [34].  As such, the tobacco industry 448 
typically designs cigarettes to have a large proportion of unprotnonated nicotine for inhalation to 449 
enhance lung deposition and delivery to the brain [35].  Consequently, when the surfactant film is in 450 
the uncompressed state (i.e. with the individual surfactant molecules decidedly exposed for 451 
interaction) neutral nicotine could potentially weaken intermolecular van der Waals forces and 452 
cause structural destabilisation, which will ultimately increase the compressibility of the material 453 
(i.e. cause it to be less rigid) [33].  454 
Tobacco-specific nitrosamines can also have a detrimental impact on the mechanical properties of 455 
surfactant monolayers (i.e. by degrading individual phospholipid molecules) [36].  For example, NNN 456 
and NNK are primary carcinogenic tobacco-specific nitrosamines that are present in cigarette smoke 457 
[37].  Upon interaction with a surfactant film, these agents enhance phospholipid hydrolysis and 458 
subsequently reduce content within the alveolar space; an accompanied increase in 459 
lysophospholipid is also noted [28].  Within the body, lysophospholipids are formed as a result of 460 
phospholipase A2 stereoselective hydrolysis of the ester linkage of phospholipids to release fatty 461 
acids and lysophospholipids [38].  The lysophospholipids produced also have a direct detergent-like 462 
effect on the surfactant leading to impaired surface activity and consequently lead to a reduction in 463 
rigidity across the two-dimensional plane [21].   464 
 465 
 466 
 467 
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3.4 Langmuir Pressure – Area Isocycles 468 
 469 
Langmuir pressure-area isocycles were also recorded for each system under conditions reflective of 470 
the in vivo scenario such that the impact of smoke vapour on surfactant dynamics could be assessed; 471 
representative plots are presented in Figures 7, 8 and 9.  Again, the presence of cigarette / e-472 
cigarette vapour within the test zone did impact simulated pulmonary surfactant function.   In each 473 
case, the surfactant film exhibits a condensed character and the ability to lower the surface tension 474 
at all stages throughout compression is weakened. 475 
 476 
 477 
Figure 7.   Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant 478 
monolayer to cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated 479 
relative humidity.  Averaged data of 3 replicates presented with standard error of the mean displayed.  Where, 480 
each replicate consists of 10 compression-expansion cycles at a barrier speed of 100cm2 / min. 481 
 482 
With regard to the baseline systems (i.e. Langmuir isocycles in the absence of cigarette / e-cigarette 483 
vapour), the maximum recorded surface pressure was 36mN/m during this work on addition of 10µl 484 
spreading solution to the surface of the supporting aqueous subphase.  This value is comparable to 485 
that previously observed for the Langmuir isotherm element of this study, with the slight reduction 486 
due to monolayer pre-conditioning (i.e. the execution of 4 compression – expansion cycles) to attain 487 
the equilibrium state.   488 
 489 
 490 
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Following exposure to cigarette vapour, the ability of the simulated pulmonary surfactant film to 491 
reduce the surface tension term was impaired at all relative trough areas.  The result may be 492 
ascribed to a reduction in the total phospholipid / lipid content of the surfactant film [14 & 21].  493 
Moreover, if the gradient of the trace between the surface pressures of 10mN/m and 30mN/m is 494 
considered, it is apparent that the surfactant film exposed to the cigarette vapour is less 495 
compressible (i.e. harder to compress) when compared to the baseline isotherm.  Thus, the data 496 
indicate that exposure to cigarette vapour increases the work required to compress the simulated 497 
pulmonary surfactant monolayer to the minimum trough area. 498 
On expansion, the simulated pulmonary surfactant monolayer exposed to cigarette smoke followed 499 
a similar pattern to that of the baseline system.  The result confirms that the material is able to 500 
respread after exposure to smoke vapour.  Furthermore, the apparent hysteresis between 501 
compression and expansion cycles was constant.  Interestingly, the difference in collapse pressure 502 
before and after exposure to smoke was less significant compared to the single compression 503 
isotherm presented in Figure 4; in this case only an 11% reduction was calculated for the term.  We 504 
attribute this result to a ‘protective mechanism’ on dynamic monolayer compression – expansion 505 
cycling and suggest that the lipid peroxidation effects contribute to the chemical degradation of the 506 
POPG molecule that is primarily responsible for maintaining the fluidity of the surfactant film. 507 
Following exposure to e-cigarette vapour, the simulated pulmonary surfactant monolayers were not 508 
significantly degraded and once again displayed condensed character as illustrated in Figures 8 and 509 
9.  Here, the ability to lower the surface tension term at all relative areas was reduced, as previously 510 
noted in the case of the cigarette vapour addition.  In contrast to the previous system, the data 511 
confirm that the maximum surface pressure of 36mN/m is attained subsequent to e-cigarette 512 
vapour exposure.  Thus, there is limited impact on attaining the maximum surface pressure value. 513 
 514 
20 | P a g e  
 
 515 
Figure 8.   Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant 516 
monolayer to 1st generation e-cigarette vapour addition under physiologically relevant conditions, namely 37°C 517 
and elevated relative humidity.  Averaged data of 3 replicates presented with standard error of the mean 518 
displayed.  Where, each replicate consists of 10 compression-expansion cycles at a barrier speed of 100cm2 / 519 
min. 520 
 521 
 522 
Figure 9.   Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant 523 
monolayer to 3rd generation e-cigarette vapour addition under physiologically relevant conditions, namely 37°C 524 
and elevated relative humidity.  Averaged data of 3 replicates presented with standard error of the mean 525 
displayed. 526 
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We attribute the apparent deviation between each Langmuir isocycle to both the loss / degradation 527 
of amphiphilic material at the air-liquid interface and the penetration of nicotine molecules between 528 
the polar head groups of the constituent molecules [11 & 33].  The reduction in the surface pressure 529 
is more pronounced upon exposure to the vapour generated from the 1st generation e-cigarette.  530 
Here, there is a clear translocation to the left within the plot when compared with baseline starting 531 
from approximately 1mN/m up towards 28mN/m.  Such deviation is not as apparent shift in the case 532 
of exposure to 3rd generation e-cigarette vapour.  In the case of exposure to both 1st and 3rd 533 
generation e-cigarette vapour exposure, the hysteresis between the expansion and compression 534 
phases are of similar sizes to that presented within the baseline.  535 
 536 
3.4.1 Langmuir Isocycle Compressibility Analysis 537 
 538 
In a similar fashion to that previously described, consideration was given to the quantitative 539 
determination of the influence cigarette / e-cigarette vapour had on simulated pulmonary surfactant 540 
compressibility during active cycling; once again Equation 1 was applied.  Here, the slope of the 541 
Langmuir pressure-area isocycle was considered along the liquid-expanded to liquid-condensed 542 
transition.  That is to say, between the surface pressures of 10mN/m to 30mN/m at the specific 543 
relative trough areas of 40%, 50% and 70%.  Compressibility data for each system is presented in 544 
Figure 10. 545 
 546 
Figure 10. The compressibility of simulated pulmonary surfactant monolayers at pre-defined relative trough 547 
areas in the absence and presence of cigarette / e-cigarette vapour.  In all cases of repeated monolayer 548 
compression-expansion (i.e. Langmuir isocycles), the delivery of such vapour to the test zone decreased the 549 
compressibility term. 550 
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Following exposure to cigarette / e-cigarette vapour, the compressibility term decreased.  Lower 551 
compressibility values indicate that the surfactant film became more rigid in character and thus 552 
harder to compress when compared to the baseline.  This effect was more pronounced in the case of 553 
the 1st generation e-cigarette vapour, demonstrating a potentially greater adverse effect on 554 
pulmonary surfactant activity.  As per previously noted, the influence on monolayer compressibility 555 
is minimal in the case of the 3rd generation e-cigarette; this point supports the usefulness of the 556 
more recently developed electronic products (e.g. PREPs) to support harm reduction within the 557 
population. 558 
The use of Langmuir isocycles closely represents the in vivo scenario.  In this case, the collection of 559 
amphiphilic molecules experience a two-dimensional lateral force on trough barrier movement to 560 
the centre of the compartment with the phospholipid head groups less accessible to environmental 561 
toxins and hence may be described as ‘protected’.  During surfactant compression-expansion cycles, 562 
the fluid phase associated with surface active material is rapidly exchanged between the monolayer 563 
interface and the adjoining surface associated reservoir [14 & 31].  As the monolayer is compressed, 564 
the increase in surface pressure directs a fraction of the unsaturated lipid component (i.e. POPG) 565 
away from the interfacial zone to desorb into the surface-associated, multilayer reservoir [39].  On 566 
expansion, these fluid phase components stored in the surface associated reservoir support the 567 
readsorption of the lipid fraction back to the interfacial zone [31].  The presence of cigarette / e-568 
cigarette vapour within the vicinity of a surfactant film inhibits such exchange mechanisms and 569 
therefore alters the proportion of phospholipids within the two-dimensional monolayer [14].  As 570 
such, the mechanical properties of the monolayer film are adversely affected (i.e. there is an 571 
apparent increase in film rigidity) which ultimately impairs the surface tension lowering capacity of 572 
the material [11]. 573 
This point is confirmed by the apparent decrease in monolayer compressibility and impairment in 574 
the ability to reduce the surface tension term at all relative trough areas.  A number of mechanisms 575 
have been proposed to explain such findings and include for example the presence of oxygen 576 
derived free radicals within cigarette vapour that are capable of reducing the amount of unsaturated 577 
lipids (i.e. POPG) within the two-dimensional ensemble via peroxidation of double carbon-carbon 578 
bonds within the acyl chains [40].  The net result is the presentation of a rigid interface that is high in 579 
solid phase domains.  This type of reaction involves the oxidative degradation of the amphiphilic 580 
species by free radicals contained within cigarette vapour [41].   581 
 582 
 583 
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The oxidation of unsaturated components within a lipid monolayer (i.e. the exposed acyl chain 584 
groups of the ensemble) is anticipated due to the availability of multiple double bonds accompanied 585 
by methylene bridges that possess especially reactive hydrogen atoms [42].  Naturally, a reduction in 586 
the liquid phase within a rigid monolayer leads to poor respread profile on expansion and reduced 587 
surfactant coverage at the air-liquid interface [43].  588 
The data presented within this study clearly demonstrate that exposure to cigarette / e-cigarette 589 
vapour has a detrimental impact on the activity of a simulated pulmonary surfactant film.  The 590 
amphiphilic material forming the surfactant monolayer is central to the regulation of the surface 591 
tension parameter at the alveolar air-liquid interface [14 & 21].  As such, if we take the findings 592 
presented within this study and extrapolate to the in vivo scenario, an increase in the work of 593 
breathing would be anticipated.  The net effect of this would be impaired lung function, which could 594 
manifest as compromised gaseous exchange within the (deep) lung, potential collapse or incomplete 595 
inflation of the lung structure itself, hypoxia, oedema and quite possibly pulmonary hypertension [41 596 
& 44].  Furthermore, due to such deviation from the healthy state, scope exists for longstanding 597 
conditions to develop including for example chronic obstructive pulmonary disease (COPD) along 598 
with interstitial lung disease.  Overall, impairment to lung mechanics would be expected [44].  599 
Indeed, previous work has confirmed significant reductions in phospholipid concentrations in the 600 
bronchoalveolar lavage fluid obtained from those who smoke cigarettes and experience COPD [45 & 601 
46].  Thus, the lung-specific adverse effects associated with cigarette smoking can reduce the quality 602 
of life of the individual and increase the likelihood of premature death. 603 
Over the course of recent years, e-cigarettes have become increasingly popular within developed 604 
countries because of the possibility of delivering nicotine to the body in a clean format whilst 605 
concurrently satisfying behavioural triggers [17, 29 & 47].  In relation to this point, during 2014 Safari 606 
and co-workers documented the fact that e-cigarettes can reliably deliver nicotine to the lung whilst 607 
limiting the exposure to tobacco specific toxins when compared with traditional cigarettes and the 608 
use of hence it is a healthier alternative from a public health perspective [48].  However, potential 609 
drawbacks to the wide spread uptake of e-cigarettes involve the lack of quality control and 610 
manufacturing regulations currently in place.  For instance, such regulations do not fully cover 611 
aspects comprising raw material inclusion, purification stages and batch-to-batch consistency of e-612 
liquid refills; all of which can impact upon the vapour profile from the respective products [17, 18, 48 613 
& 49].   Clearly, these elements require further detailed investigation. 614 
 615 
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Although not reported here, some commercially available e-liquid and cartridge refills do contain 616 
chemicals that may pose potential health risks to the individual; interestingly these agents have also 617 
been detected within tobacco smoke vapour [16, 17, 18, 27, 47 & 48].  For example, the cytotoxic 618 
and carcinogenic substances including formaldehyde, NNN, NNK and acrolein have been identified 619 
within e-cigarette vapour; all may have deleterious effects on the human body [16, 17 & 48].  620 
Although the concentration of such substances is much lower than in traditional cigarette vapour, 621 
alteration of pulmonary surfactant activity is possible at the alveolar air-liquid interface and this can 622 
in turn initiate the presentation and development of the lung related complications / disease states 623 
listed above [1, 11 & 50]. 624 
 625 
     4.    Conclusion  626 
 627 
This study has demonstrated that exposure to cigarette / e-cigarette vapour does modify the 628 
structure-function activity of simulated pulmonary surfactant monolayers under physiologically 629 
relevant conditions.  The results offer insight into the potential effects such (environmental) toxins 630 
can have on the human lung.  With reference to the dynamic system investigated herein, the 631 
capacity to reduce the surface tension term was impaired throughout and the compressibility of the 632 
surfactant film was reduced in all cases.  The findings were ascribed to the chemical interactions 633 
taking place between pulmonary surfactant-specific components and the smoke vapour delivered to 634 
the test zone.  We propose key mechanisms of interaction include: a) nicotine insertion into the two-635 
dimensional phospholipid ensemble, b) lipid peroxidation of the amphiphilic acyl chains and c) 636 
hydrolysis of the phospholipid chains via tobacco-specific nitrosamine association.   637 
Detrimental interactions such as these can cause molecular destabilisation and inhibit phospholipid 638 
exchange with the surface associated reservoir system.  Correspondingly, a reduction in lung 639 
compliance can lead to the development of a range of lung specific complications including 640 
pulmonary oedema and COPD; the latter condition is frequently noted with the chronic smoker.  641 
Undoubtedly, further work is required to gain greater insight into the delicate interplay between 642 
environmental toxins and the pulmonary space.  Such investigation may now be readily conducted 643 
via use of the lung biosimulator platform presented within this piece.  Here, scope exists to consider 644 
the influence of a wide range of environmental toxins have on lung function, including for example 645 
petrol and diesel fumes.  This device also holds potential to quantitatively probe the interaction 646 
between respirable therapeutic formulations and the deep lung (e.g. in pharmaceutical dissolution 647 
testing).   648 
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